As filed with the Securities and Exchange Commission on April 1, 2014
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 
FORM N-Q
 
 
QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY
 



Investment Company Act file number 811-07959



Advisors Series Trust
(Exact name of registrant as specified in charter)



615 East Michigan Street
Milwaukee, WI 53202
(Address of principal executive offices) (Zip code)



Douglas G. Hess, President
Advisors Series Trust
c/o U.S. Bancorp Fund Services, LLC
777 East Wisconsin Avenue, 5 th Floor
Milwaukee, WI 53202

(Name and address of agent for service)


(414) 765-6609
Registrant's telephone number, including area code



Date of fiscal year end:   April 30, 2014



Date of reporting period:   January 31, 2014

 
 
 
 

 
 
Item 1. Schedules of Investments.
 
SiM Dynamic Allocation Diversified Income Fund
 
Schedule of Investments
 
at January 31, 2014 (Unaudited)
 
           
Shares
     
Value
 
   
EXCHANGE-TRADED FUNDS - 92.4%
     
   
Equity ETFs - 36.9%
     
                   3,454
 
Health Care Select Sector SPDR Fund
  $ 193,286  
                   3,980
 
iShares Cohen & Steers Realty Majors Index Fund
    311,156  
                 33,466
 
iShares Mortgage Real Estate Capped ETF
    407,951  
                   6,585
 
iShares MSCI EAFE Index Fund
    418,872  
                   4,804
 
iShares MSCI Emerging Markets Index
    183,465  
                   5,406
 
iShares Russell 1000 Growth Index Fund
    451,292  
                   3,947
 
iShares Russell 1000 Value Index Fund
    358,348  
                   1,980
 
iShares Russell 2000 Growth Index Fund
    263,993  
                   1,873
 
iShares Russell 2000 Value Index Fund
    179,134  
                   2,688
 
iShares Russell Midcap Growth Index Fund
    221,652  
                   2,814
 
iShares Russell Midcap Value Index Fund
    181,531  
                   6,014
 
SPDR Barclays Capital Convertible Securities ETF
    284,402  
                   5,334
 
SPDR S&P BRIC 40 ETF
    114,254  
                   5,880
 
Technology Select Sector SPDR Fund
    204,742  
                   1,875
 
Utilities Select Sector SPDR
    73,313  
                   4,806
 
Vanguard Growth ETF
    433,357  
                   5,777
 
Vanguard Value ETF
    425,014  
          4,705,762  
   
Fixed Income ETFs - 55.5%
       
                   2,857
 
iShares Barclays 7-10 Year Treasury Bond Fund
    292,214  
                   8,459
 
iShares Barclays Credit Bond Fund
    919,662  
                 12,664
 
iShares Barclays MBS Bond Fund
    1,349,096  
                   2,558
 
iShares Barclays TIPS Bond Fund
    287,033  
                   9,683
 
iShares iBoxx $ High Yield Corporate Bond Fund
    902,940  
                   9,667
 
iShares iBoxx $ Investment Grade Corporate Bond Fund
    1,124,659  
                   6,345
 
iShares JP Morgan USD Emerging Markets Bond Fund
    680,819  
                 16,137
 
iShares S&P U.S. Preferred Stock Index Fund
    611,915  
                 22,219
 
SPDR Barclays Capital High Yield Bond ETF
    906,313  
          7,074,651  
   
TOTAL EXCHANGE-TRADED FUNDS (Cost $11,023,772)
    11,780,413  
             
Principal Amount
           
   
CORPORATE BONDS - 6.8%
       
   
Accommodation and Food Services - 2.4%
       
   
MGM Resorts International
       
 $ 275,000
 
7.75%, 3/15/22
    310,750  
   
Health Care and Social Assistance - 2.6%
       
   
Kindred Healthcare, Inc.
       
305,000
 
8.25%, 6/1/19
    328,638  
   
Professional, Scientific, and Technical Services - 1.8%
       
   
Griffey Intermediate, Inc.
       
295,000
 
7.00%, 10/15/20 (b)
    231,575  
   
TOTAL CORPORATE BONDS (Cost $903,609)
    870,963  
             
   
SHORT-TERM INVESTMENTS - 1.5%
       
               194,507
 
Fidelity Institutional Money Market Portfolio - Class I, 0.04% (a)
    194,507  
   
TOTAL SHORT-TERM INVESTMENTS (Cost $194,507)
    194,507  
             
   
Total Investments in Securities (Cost $12,121,888) - 100.7%
    12,845,883  
   
Liabilities in Excess of Other Assets - (0.7)%
    (91,922 )
   
NET ASSETS - 100.0%
  $ 12,753,961  
             
   
ETF - Exchange-Traded Fund
       
   
(a) Rate shown is the 7-day annualized yield as of January 31, 2014.
       
   
(b) Security purchased within the terms of a private placement memorandum, exempt from registration under Rule 144A of the Securites Act of 1933, as amended, and may be sold only to dealers in the program or other "qualified institutional buyers." Strategic Income Management, LLC, the Fund's adviser, has determined that such security is liquid in accordance with the liquidity guidelines approved by the Board of Trustees of Advisors Series Trust.  As of January 31, 2014, the value of these investments was $231,575 or 1.8% of net assets.
 
 

 
 
 

 
 
SiM Dynamic Allocation Equity Income Fund
 
Schedule of Investments
 
at January 31, 2014 (Unaudited)
 
           
Shares
     
Value
 
   
EXCHANGE-TRADED FUNDS - 95.8%
     
   
Equity ETFs - 85.5%
     
                 28,241
 
Health Care Select Sector SPDR Fund
  $ 1,580,366  
                 24,975
 
iShares Cohen & Steers Realty Majors Index Fund
    1,952,546  
                 73,020
 
iShares Mortgage Real Estate Capped ETF
    890,114  
                 47,552
 
iShares MSCI EAFE Index Fund
    3,024,783  
                 31,203
 
iShares MSCI Emerging Markets Index
    1,191,643  
                 39,268
 
iShares Russell 1000 Growth Index Fund
    3,278,092  
                 28,872
 
iShares Russell 1000 Value Index Fund
    2,621,289  
                 16,127
 
iShares Russell 2000 Growth Index Fund
    2,150,213  
                 18,242
 
iShares Russell 2000 Value Index Fund
    1,744,665  
                 21,721
 
iShares Russell Midcap Growth Index Fund
    1,791,114  
                 15,625
 
iShares Russell Midcap Value Index Fund
    1,007,969  
                 23,698
 
SPDR Barclays Capital Convertible Securities ETF
    1,120,678  
                 40,367
 
SPDR S&P BRIC 40 ETF
    864,661  
                 48,769
 
Technology Select Sector SPDR Fund
    1,698,137  
                 18,019
 
Utilities Select Sector SPDR
    704,543  
                 37,409
 
Vanguard Growth ETF
    3,373,169  
                 43,248
 
Vanguard Value ETF
    3,181,754  
          32,175,736  
   
Fixed Income ETFs - 10.3%
       
                   1,135
 
iShares Barclays 7-10 Year Treasury Bond Fund
    116,088  
                   3,756
 
iShares Barclays Credit Bond Fund
    408,352  
                   6,302
 
iShares Barclays MBS Bond Fund
    671,353  
                   1,026
 
iShares Barclays TIPS Bond Fund
    115,127  
                   5,437
 
iShares iBoxx $ High Yield Corporate Bond Fund
    507,000  
                   4,831
 
iShares iBoxx $ Investment Grade Corporate Bond Fund
    562,039  
                   3,307
 
iShares JP Morgan USD Emerging Markets Bond Fund
    354,841  
                 16,725
 
iShares S&P U.S. Preferred Stock Index Fund
    634,212  
                 12,574
 
SPDR Barclays Capital High Yield Bond ETF
    512,893  
          3,881,905  
   
TOTAL EXCHANGE-TRADED FUNDS (Cost $28,533,822)
    36,057,641  
             
Principal Amount
           
   
CORPORATE BONDS - 1.0%
       
   
Health Care and Social Assistance - 1.0%
       
   
Kindred Healthcare, Inc.
       
 $ 355,000
 
8.25%, 6/1/19
    382,513  
   
TOTAL CORPORATE BONDS (Cost $350,563)
    382,513  
             
   
SHORT-TERM INVESTMENTS - 3.4%
       
            1,263,706
 
Fidelity Institutional Money Market Portfolio - Class I, 0.04% (a)
    1,263,706  
   
TOTAL SHORT-TERM INVESTMENTS (Cost $1,263,706)
    1,263,706  
             
   
Total Investments in Securities (Cost $30,148,091) - 100.2%
    37,703,860  
   
Liabilities in Excess of Other Assets - (0.2)%
    (87,929 )
   
NET ASSETS - 100.0%
  $ 37,615,931  
             
   
ETF - Exchange-Traded Fund
       
   
(a) Rate shown is the 7-day annualized yield as of January 31, 2014.
       

 
 
 
 
 

 
 
SiM Dynamic Allocation Funds
Notes to Schedule of Investments
January 31, 2014 (Unaudited)

Note 1 – Securities Valuation

The SiM Dynamic Allocation Funds’ (the “Funds”) investments in securities are carried at their fair value. Equity securities, including common stocks, REITs, and exchange-traded funds, that are primarily traded on a national securities exchange shall be valued at the last sales price on the exchange on which they are primarily traded on the day of valuation or, if there has been no sale price on such day, at the mean between the bid and asked prices. Securities primarily traded in the NASDAQ Global Market System for which market quotations are readily available shall be valued using the NASDAQ Official Closing Price (“NOCP”). If the NOCP is not available, such securities shall be valued at the last sale price on the day of valuation, or if there has been no sale on such day, at the mean between the bid and asked prices. Over-the-counter securities which are not traded in the NASDAQ Global Market System shall be valued at the most recent sales price.  Investments in open-end mutual funds are valued at their net asset value per share. To the extent these securities are actively traded and valuation adjustments are not applied, they are categorized in level 1 of the fair value hierarchy.

Corporate bonds, including listed issues, are valued at market on the basis of valuations furnished by an independent pricing service which utilizes both dealer-supplied valuations and formula-based techniques.  The pricing service may consider recently executed transactions in securities of the issuer or comparable issuers, market price quotations (where observable), bond spreads, and fundamental data relating to the issuer.  Most corporate bonds are categorized in level 2 of the fair value hierarchy.

Short-term securities having a maturity of 60 days or less are valued at their amortized cost, which approximates market value.  To the extent the inputs are observable and timely, these securities would be classified in level 2 of the fair value hierarchy.

The Board of Trustees (“Board”) has delegated day-to-day valuation issues to a Valuation Committee of the Trust which is comprised of representatives from U.S. Bancorp Fund Services, LLC, the Funds’ administrator.  The function of the Valuation Committee is to value securities where current and reliable market quotations are not readily available or the closing price does not represent fair value by following procedures approved by the Board.  These procedures consider many factors, including the type of security, size of holding, trading volume and news events.  All actions taken by the Valuation Committee are subsequently reviewed and ratified by the Board.

Depending on the relative significance of the valuation inputs, fair valued securities may be classified in either level 2 or level 3 of the fair value hierarchy.

The Funds have adopted authoritative fair value accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value.  These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion in changes in valuation techniques and related inputs during the period and expanded disclosure of valuation levels for majority security types.  These inputs are summarized in the three broad levels listed below:

·
Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that the Funds have the ability to access.
 
·
Level 2 - Observable inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly or indirectly.  These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
·
Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.
 

 
 
 

 
 
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.  The following is a summary of the inputs used to value the Funds’ securities as of January 31, 2014:

SiM Dynamic Allocation Diversified Income Fund
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Exchanged-Traded Funds
                       
  Equity
  $ 4,705,762     $ -     $ -     $ 4,705,762  
  Fixed Income
    7,074,651       -       -       7,074,651  
Total Exchange-Traded Funds
    11,780,413       -       -       11,780,413  
Corporate Bonds
    -       870,963       -       870,963  
Short-Term Investments
    194,507       -       -       194,507  
Total Investments in Securities
  $ 11,974,920     $ 870,963     $ -     $ 12,845,883  

SiM Dynamic Allocation Equity Income Fund
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Exchanged-Traded Funds
                       
  Equity
  $ 32,175,736     $ -     $ -     $ 32,175,736  
  Fixed Income
    3,881,905       -       -       3,881,905  
Total Exchange-Traded Funds
    36,057,641       -       -       36,057,641  
Corporate Bonds
    -       382,513       -       382,513  
Short-Term Investments
    1,263,706       -       -       1,263,706  
Total Investments in Securities
  $ 37,321,347     $ 382,513     $ -     $ 37,703,860  

Refer to the Funds’ Schedule of Investments for a detailed break-out of securities.  Transfers between levels are recognized at January 31, 2014, the end of the reporting period.  The Funds recognized no transfers to/from Level 1 or Level 2.  There were no Level 3 securities held in the Funds during the period ended January 31, 2014.
 

 
 
 

 
 
Note 2 – Federal Income Taxes

The cost basis of investments for federal income tax purposes at January 31, 2014 was as follows*:

SiM Dynamic Allocation Diversified Income Fund

Cost of investments
  $ 12,002,143  
         
Gross unrealized appreciation
  $ 1,070,551  
Gross unrealized depreciation
    (226,811 )
Net unrealized appreciation
  $ 843,740  

SiM Dynamic Allocation Equity Income Fund

Cost of investments
  $ 29,841,756  
         
Gross unrealized appreciation
  $ 8,145,773  
Gross unrealized depreciation
    (283,669 )
Net unrealized appreciation
  $ 7,862,104  

*
Because tax adjustments are calculated annually, the above tables reflect the tax adjustments outstanding at the Funds’ previous fiscal year end.  For the previous fiscal year’s federal income tax information, please refer to the Notes to Financial Statements section in the Funds’ most recent annual or semi-annual report.
 

 
 
 

 
 
Item 2. Controls and Procedures.
 
(a)  
The Registrant’s President/Principal Executive Officer and Treasurer/Principal Financial Officer have concluded that the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “1940 Act”)) (17 CFR 270.30a-3(c)) are effective as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rule 13a-15(b) or Rule 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(d)) .

(b)  
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) (17 CFR 270.30a-3(d))   that occurred during the Registrant's last fiscal quarter that has materially affected, or are reasonably likely to materially affect, the Registrant's internal control over financial reporting.

Item 3. Exhibits.
 
Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the 1940 Act (17 CFR 270.30a-2(a)).   Filed herewith.
 
 
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


(Registrant)   Advisors Series Trust                                                                                                                                                

 
By (Signature and Title)* /s/ Douglas G. Hess                                                                                                                                       
           Douglas G. Hess, President

Date­­  3/10/14                                                                                                                                                                            



Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)* /s/ Douglas G. Hess                   
   Douglas G. Hess, President

Date  3/10/14                                                                                                                                                                                               

 
By (Signature and Title)* /s/ Cheryl L. King                                                                                                                      
   Cheryl L. King, Treasurer

Date  3/10/14                                                                            
 
* Print the name and title of each signing officer under his or her signature.
 
 
 

Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Cellular Biomedicine Charts.
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Cellular Biomedicine Charts.